SU822828A1 - Diagnostic agent for investigating secretory function of stomach and duodenum - Google Patents
Diagnostic agent for investigating secretory function of stomach and duodenum Download PDFInfo
- Publication number
- SU822828A1 SU822828A1 SU752153092A SU2153092A SU822828A1 SU 822828 A1 SU822828 A1 SU 822828A1 SU 752153092 A SU752153092 A SU 752153092A SU 2153092 A SU2153092 A SU 2153092A SU 822828 A1 SU822828 A1 SU 822828A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- stomach
- drug
- secretory function
- duodenum
- proposed
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Изобретение относитс к медицине и может быть использовано при гастроэнтерологических исследовани х.The invention relates to medicine and can be used in gastroenterological research.
Известен 2-амино-5(2-аминоэтил)-1 ,3,4-тиадиазол в качестве химического соединени Yj .2-amino-5 (2-aminoethyl) -1, 3,4-thiadiazole is known as a chemical compound Yj.
Цель изобретени - расширение ассортимента диагностических средств дл исследовани секреторной функции желудка и двенадцатиперстной кишки.The purpose of the invention is to expand the range of diagnostic tools for the study of gastric and duodenal secretory function.
Эта цель достигаетс путем применени 2-амино-5(2-аминоэтил)-1,3,4-тиадиазола в качестве диагностического средства, дл исследовани секреторной функции желудка и двенадцатиперст-ной кишки.This goal is achieved by using 2-amino-5 (2-aminoethyl) -1,3,4-thiadiazole as a diagnostic tool to study the secretory function of the stomach and duodenum.
Вли ние препарата на Н2-рецепторы желудка исследуетс на собаках-самцах . Препарат ввод т многократно внутримышечно животным с пустым желудком . Результаты опытов показы-вают , что препарат обладает сильным стимулирующим действием на желудочную секрецию. Минимальна активна доза при внутримышечном введении, привод ща к по влению кислого желудочного сока., равна 0,005 мг/кг, максимальна - 0,08 мг/кг. Часова . выработка сол ной кислоты максимальна составл ет 1,4 mqV/ч.The effect of the drug on the H2 receptors of the stomach is examined in male dogs. The drug is administered repeatedly intramuscularly to animals with an empty stomach. The results of experiments show that the drug has a strong stimulating effect on gastric secretion. The minimum active dose for intramuscular administration, resulting in the appearance of acidic gastric juice, is 0.005 mg / kg, the maximum is 0.08 mg / kg. Chasov. the maximum hydrochloric acid production is 1.4 mqV / h.
Максимальна выработка пепсина под вли нием препарата составл ет 110 мг за 1 ч. Средство обладает выраженным действием на Н -рецепторы желудка, препарат -способен вы чвать секрецию при приеме внутрь. Расслабл ющее действие препарата на Н2-рецепторы гладкой мускулатуры изолированного рога матки составл 0 ет 15%i Препарат обладает слабовыраженной гис.таминоподобной активностью на Н -рецепторы кишечника.The maximum production of pepsin under the influence of the drug is 110 mg per 1 hour. The drug has a pronounced effect on the H-receptors of the stomach, the drug is capable of extracting secretion when taken orally. The relaxing effect of the drug on the H2 receptors of the smooth muscles of the isolated horn of the uterus is 15%. I The preparation has a weakly expressed histamine-like activity on the intestinal H receptors.
дл вы снени действи препарата на гистаминовые рецепторы сердечно5 сосудистой системы провод тс опыты на кошках и кроликах.To investigate the effect of the drug on the histamine receptors of the cardiovascular 5 system, experiments on cats and rabbits were carried out.
Кошкам весом 2,5-4 кг, наркотизированным уретано-хлоралоэовым наркозом внутрибрюшинно,артериальное дав0 ление регистрируют в общей сонной артерии ртутным манометром. Все вещества ввод тс внутривенно. Внутривенное введение препаратов в дозе 0., 1 мг/кг наркотизированной кошке For cats weighing 2.5-4 kg, anesthetized with urethane-chloraeic anesthesia intraperitoneally, blood pressure is recorded in the common carotid artery with a mercury manometer. All substances are administered intravenously. Intravenous administration of drugs in a dose of 0., 1 mg / kg anesthetized cat
5 приводит к снижению артериа.пьного давлени от первоначального уровн на 30 мм рт..ст. предлагаемого препарата . В дозах, меньших 0,1 мг/кг, гипотензивного эффекта почти не на- . 5 results in a decrease in arterial pressure from the initial level of 30 mm Hg. the proposed drug. At doses of less than 0.1 mg / kg, the hypotensive effect was almost absent.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU752153092A SU822828A1 (en) | 1975-07-02 | 1975-07-02 | Diagnostic agent for investigating secretory function of stomach and duodenum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU752153092A SU822828A1 (en) | 1975-07-02 | 1975-07-02 | Diagnostic agent for investigating secretory function of stomach and duodenum |
Publications (1)
Publication Number | Publication Date |
---|---|
SU822828A1 true SU822828A1 (en) | 1981-04-23 |
Family
ID=20625589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU752153092A SU822828A1 (en) | 1975-07-02 | 1975-07-02 | Diagnostic agent for investigating secretory function of stomach and duodenum |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU822828A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4543339A (en) * | 1982-03-16 | 1985-09-24 | Oneill Christopher | Early pregnancy detection by detecting enhanced blood platelet activation |
-
1975
- 1975-07-02 SU SU752153092A patent/SU822828A1/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4543339A (en) * | 1982-03-16 | 1985-09-24 | Oneill Christopher | Early pregnancy detection by detecting enhanced blood platelet activation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Woody et al. | Lithium toxicity in a newborn | |
LEVINE et al. | Pressor amines and the carcinoid flush | |
Bennett et al. | Analysis of the motor effects of gastrin and pentagastrin on the human alimentary tract in vitro. | |
Moore et al. | Naloxone: underdosage after narcotic poisoning | |
Mirkin | Placental transfer and neonatal elimination of diphenylhydantoin | |
Peters et al. | The relation of albuminuria to protein requirement in nephritis | |
Bluntschli, HJ*** & Goetz | The effect of a new sympathicolytic drug (dihydroergocornine) on the blood-pressure with special reference to hypertension | |
Mir et al. | Response to atropine in Down's syndrome | |
SU822828A1 (en) | Diagnostic agent for investigating secretory function of stomach and duodenum | |
Young et al. | Renal Excretion of Methonium Compounds | |
Wilson | Differences during dicoumarol therapy in the Quick and Russell viper venom methods for prothrombin determination. | |
Schofield et al. | Leucopenia and fever in the" Jarisch-Herxheimer" reaction of louse-borne relapsing fever | |
JP2549480B2 (en) | Urinary disorder improving agent | |
Johnston et al. | The control of high blood pressure during labour with clonidine (“catapres”) | |
Wilkins | Veratrum viride and essential hypertension | |
Merritt et al. | Basal and histamine-induced gastric acid and pepsin secretion in the conscious miniature pig | |
DeLamater | Acute Exfoliative Dermatitis Due to Dormison® | |
JPH05504130A (en) | Tumor necrosis factor antagonist | |
Hendon | Venoclysis | |
Barr et al. | Effect of diazoxide on the antepartum cardiotocograph in severe pregnancy‐associated hypertension | |
Catz et al. | Environmental factors: Pharmacology | |
RU2163122C1 (en) | Medicinal agent | |
GROPPER et al. | EFFECTS OF VERILOID® ON ESSENTIAL HYPERTENSION: A New Derivative of Veratrum Viride | |
Lumbers et al. | Tachyphylaxis to angiotensin in man | |
FOSTER et al. | THE TREATMENT OF ACUTE TYPHOID FEVER WITH CHLOROMYCETIN® |